For chronic subdural hematoma, what is the recommended duration of dexamethasone therapy?

Dexamethasone Should NOT Be Given for Chronic Subdural Hematoma

Based on the highest quality and most recent evidence, dexamethasone is contraindicated in the treatment of chronic subdural hematoma (CSDH) and should not be administered. Two large, high-quality randomized controlled trials published in 2020 and 2023 definitively demonstrate that dexamethasone results in worse functional outcomes, more complications, and higher rates of subsequent surgical intervention compared to standard treatment 1, 2.

Key Evidence Against Dexamethasone Use

The 2020 Dex-CSDH trial enrolled 748 patients and assigned them to either a 2-week tapering course of dexamethasone (starting at 8 mg twice daily) or placebo 1. The results were unequivocally negative:

• Worse functional outcomes: Only 83.9% of dexamethasone patients achieved favorable outcomes (modified Rankin Scale 0-3) compared to 90.3% in the placebo group—an absolute difference of -6.4 percentage points (P = 0.01)
• More adverse events: Serious adverse events occurred in 16.0% of dexamethasone patients versus only 6.4% in placebo patients
• Fewer repeat operations: Paradoxically, only 1.7% required repeat surgery in the dexamethasone group versus 7.1% in placebo, but this did not translate to better overall outcomes

The 2023 DECSA trial compared dexamethasone monotherapy (19-day tapering course) directly to burr-hole drainage surgery in 252 patients 2. This trial was terminated early by the data safety monitoring board due to safety concerns:

• Failed to show noninferiority: The adjusted odds ratio for better functional outcomes with dexamethasone was 0.55 (95% CI: 0.34-0.90), demonstrating clear inferiority to surgery
• Higher complication rate: 59% of dexamethasone patients experienced complications versus 32% in the surgery group
• Massive crossover to surgery: 55% of dexamethasone patients ultimately required surgical intervention anyway, compared to only 6% requiring additional surgery in the surgery group

Clinical Algorithm: When Dexamethasone Duration is Zero

For symptomatic CSDH patients:

• Do NOT initiate dexamethasone therapy
• Proceed directly to surgical evaluation for burr-hole drainage
• 94% of patients in the Dex-CSDH trial underwent surgery, representing standard practice 1

For asymptomatic or minimally symptomatic CSDH:

• Observation with serial imaging is appropriate
• Dexamethasone still offers no benefit and should be avoided
• If symptoms develop, proceed to surgical consultation

Important Caveats and Nuances

The one potential exception involves patients with significant residual hematoma (>50% of preoperative volume) AFTER surgical drainage. A 2025 retrospective study suggested that low-dose adjuvant dexamethasone (2 mg twice daily, tapering over 3 weeks) may reduce recurrence rates in this specific post-surgical context—from 22.9% to 3.4% 3. However, this is a single retrospective study and requires prospective validation before routine adoption.

Radiological subtypes: A 2023 substudy found that hematomas without hyperdense components showed greater size reduction with dexamethasone than those with hyperdense components 4. However, this radiological finding does not translate into clinical benefit, as the parent trial demonstrated overall harm.

Common pitfall: The FDA label for dexamethasone mentions cerebral edema treatment with dosing of 10 mg IV followed by 4 mg every 6 hours 5. This indication refers to tumor-associated cerebral edema or other acute brain injuries—NOT chronic subdural hematoma. Do not conflate these distinct clinical entities.

Why the Negative Results?

The mechanism of harm likely relates to:

• Immunosuppression increasing infection risk (serious adverse events were 2.5-fold higher)
• Interference with the natural inflammatory resolution process of CSDH
• Delayed definitive treatment in patients who ultimately require surgery anyway
• Steroid-related complications (hyperglycemia, psychiatric effects, gastrointestinal bleeding) outweighing any anti-inflammatory benefit

Bottom line: The duration of dexamethasone therapy for chronic subdural hematoma is zero days. Do not prescribe it. The evidence is clear, consistent, and recent—dexamethasone causes harm in this population.